The BioPharm Brief: Hormones, Metabolism, Momentum

Jun 12, 08:01 PM
Headliner
Share
Subscribe

New clinical data highlight advances in endocrine, metabolic, and rare disease drug development, with positive updates from MBX Biosciences, Gan & Lee Pharmaceuticals, and Novartis.

Share
Subscribe
Next
The BioPharm Brief: Dual Targets, Treg Therapy, Tumor Responses
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief